{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:35:39Z","timestamp":1767875739433,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier","isbn-type":[{"value":"9780443296123","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMPTA22\/00167"],"award-info":[{"award-number":["PMPTA22\/00167"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["HR21-00761"],"award-info":[{"award-number":["HR21-00761"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2020-117323RB-100"],"award-info":[{"award-number":["PID2020-117323RB-100"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["CPP2022-009765"],"award-info":[{"award-number":["CPP2022-009765"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["CPP2022-009762"],"award-info":[{"award-number":["CPP2022-009762"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PDC2021-121711-100"],"award-info":[{"award-number":["PDC2021-121711-100"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.mcb.2025.02.012","type":"book-chapter","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T18:59:46Z","timestamp":1741892386000},"page":"167-186","source":"Crossref","is-referenced-by-count":1,"title":["Generation and functional evaluation of bispecific T cell engaging antibodies"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.mcb.2025.02.012_bib1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153192","article-title":"Combinatorial anti-tumor activity in animal models of a novel CD123 x CD3 Bispecifc Dart\u00ae molecule (MGD024) with cytarabine, venetoclax or azacitidine supports combination therapy in acute myeloid leukemia","volume":"138","author":"Alderson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2025.02.012_bib2","unstructured":"Antibody therapeutics approved or in regulatory review in the EU or US. Antibody Society. Accessed August 2024. https:\/\/www.antibodyso\/ciety.org\/resources\/approved-antibodies\/."},{"issue":"1","key":"10.1016\/bs.mcb.2025.02.012_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/1535-7163.MCT-20-0061","article-title":"TriTACs, a novel class of T-cell-engaging protein constructs designed for the treatment of solid tumors","volume":"20","author":"Austin","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.mcb.2025.02.012_bib4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"15","author":"Bargou","year":"2008","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.mcb.2025.02.012_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.mcb.2025.02.012_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","article-title":"T cell-redirecting strategies to \u2018STAb\u2019 tumors: Beyond CARs and bispecific antibodies","volume":"40","author":"Blanco","year":"2019","journal-title":"Trends in Immunology"},{"key":"10.1016\/bs.mcb.2025.02.012_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-21-0853","article-title":"Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers","volume":"1","author":"Blanco","year":"2022","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.mcb.2025.02.012_bib8","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity","volume":"15","author":"Boustany","year":"2022","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.mcb.2025.02.012_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/bs.mcb.2025.02.012_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nature Cancer"},{"key":"10.1016\/bs.mcb.2025.02.012_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004336","article-title":"Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186","volume":"10","author":"Dettling","year":"2022","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.mcb.2025.02.012_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40265-022-01704-4","article-title":"Tebentafusp: First approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/bs.mcb.2025.02.012_bib13","article-title":"Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo","volume":"14","author":"D\u00edez-Alonso","year":"2024","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.mcb.2025.02.012_bib14","article-title":"Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody","volume":"24","author":"Geiger","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/bs.mcb.2025.02.012_bib15","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.mcb.2025.02.012_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2013 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.mcb.2025.02.012_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the design of antibody-based therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/bs.mcb.2025.02.012_bib18","article-title":"Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity","volume":"17","author":"Hangiu","year":"2022","journal-title":"iScience"},{"key":"10.1016\/bs.mcb.2025.02.012_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005333","article-title":"Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers","volume":"10","author":"Jim\u00e9nez-Reinoso","year":"2022","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.mcb.2025.02.012_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/bs.mcb.2025.02.012_bib21","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.mcb.2025.02.012_bib22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The use of CrossMAb technology for the generation of bi- and multispecific antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/bs.mcb.2025.02.012_bib23","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1182\/blood-2022-168739","article-title":"Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of b-cell non-Hodgkin lymphoma","volume":"140","author":"Kuchnio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2025.02.012_bib24","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.7150\/thno.75037","article-title":"A novel Her2\/VEGFR2\/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy","volume":"14","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/bs.mcb.2025.02.012_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1890411","article-title":"TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL","volume":"13","author":"Malik-Chaudhry","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/bs.mcb.2025.02.012_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-01790-2","article-title":"Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity","volume":"4","author":"Mandrup","year":"2021","journal-title":"Communications Biology"},{"key":"10.1016\/bs.mcb.2025.02.012_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: The rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.mcb.2025.02.012_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy279.414","article-title":"Phase I study of AMG 211\/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed\/refractory gastrointestinal (GI) adenocarcinoma","volume":"29","author":"Moek","year":"2018","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology \/ ESMO"},{"key":"10.1016\/bs.mcb.2025.02.012_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.clcc.2016.07.009","article-title":"Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas","volume":"15","author":"Pishvaian","year":"2016","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1016\/bs.mcb.2025.02.012_bib31","article-title":"Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies","volume":"23","author":"Ram\u00edrez-Fern\u00e1ndez","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.mcb.2025.02.012_bib32","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1182\/blood-2022-169729","article-title":"The novel bispecific innate cell engager (ICE\u00ae) AFM28 efficiently directs allogeneic NK Cells to CD123+ leukemic stem- and progenitor cells in AML","volume":"140","author":"Schmitt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2025.02.012_bib30","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"27","author":"Tapia-Galisteo","year":"2023","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/bs.mcb.2025.02.012_bib33","article-title":"Antibody or antibody fragments: Implications for molecular imaging and targeted therapy of solid tumors","volume":"12","author":"Xenaki","year":"2017","journal-title":"Frontiers in Immunology"}],"container-title":["Methods in Cell Biology","Immuno-Oncology and Immunotherapy - Part E"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X25000706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X25000706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:38:10Z","timestamp":1763624290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X25000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443296123"],"references-count":33,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2025.02.012","relation":{},"ISSN":["0091-679X"],"issn-type":[{"value":"0091-679X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}